ArticleAnnals of surgical oncology2025
Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory Analysis.
Yawen Dong et al.PubMed ↗Publisher ↗
No numbers read from the abstract.